Abstract
Background: The potential role of bevacizumab in the treatment of ovarian granulosa-cell tumors has not been evaluated. Case: An 82 year old woman with refractory ovarian granulosa-cell carcinoma was treated with bevacizumab with symptomatic relief of ascites. Conclusion: Bevacizumab may have a role in the management of malignant ascites in the patient with refractory granulosa-cell carcinoma of the ovary which should be confirmed in a larger series of well selected patients.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 527-529 |
| Number of pages | 3 |
| Journal | Gynecologic Oncology |
| Volume | 111 |
| Issue number | 3 |
| DOIs | |
| State | Published - Dec 2008 |
All Science Journal Classification (ASJC) codes
- Oncology
- Obstetrics and Gynecology
Fingerprint
Dive into the research topics of 'The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: A case report'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver